醋酸來法莫林Lefamulin Acetate
【化學名】Lefamulin Acetate
【原研】Nabriva Therapeutics
【上市時間】2021 年 01 月 28 日
【專利到期】2033 年 03 月 18 日
【用途】社區獲得性感染，細菌性肺炎，肺炎和社區獲得性肺炎; 細菌感染。
【劑型/規格】片劑:600mg/片;注射液：150mg/15mL氯化鈉溶液
醋酸來法莫林Lefamulin Acetate
一、 產品概述
Lefamulin Acetate是由Nabriva Therapeutics研發的是一種抗生素，是一種50S核糖體亞基調節劑。2019年08月19日，Lefamulin獲得美國食品藥品管理局FDA批準，由Nabriva Therapeutics銷售，商品名為Xenleta?。
二、主要產品
Description | Structural Formula | CAS No. | Category |
Lefamulin acetate |
| 1350636-82-6 | API |
S-((1R,2R,4R)-4-((tert-butoxycarbonyl)amino)-2-hydroxycyclohexyl) benzothioate |
| 1350636-89-3 | intermediates |
S-((1R,2R,4R)-2-hydroxy-4-(2,2,2-trifluoroacetamido)cyclohexyl) benzothioate |
| 1350636-92-8 | intermediates |
TOS- pleu |
| 31716-01-5 | intermediates |
![G0O_IV(O]M_5@%XII4AQ8D3.png](https://hcfhb.com/public/upload/ueditor/images/20240428/1714287949805276.png "1714287949805276.png")
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.